Cantor Fitzgerald Reiterates Overweight on Bristol-Myers Squibb, Maintains $75 Price Target

Benzinga · 09/15/2023 12:35
Cantor Fitzgerald analyst Olivia Brayer reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight and maintains $75 price target.